Navigation Links
BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
Date:4/19/2013

Madison, WI (PRWEB) April 19, 2013

BellBrook Labs' Transcreener® HTS Assay products will be available exclusively from Cambio in the UK as of April 2013. The two companies initiated their business alliance in April of 2012, and Cambio’s rapid success in penetrating UK drug discovery laboratories with the Transcreener ADP Assay and related products prompted BellBrook to grant them exclusive distribution rights for the Transcreener products for the first time in a European country.

The revised agreement includes the full Transcreener® product line of HTS assays covering thousands of enzymes, including established target families like kinases as well as emerging target families such as methyltransferases, GTPases, and glycosyltransferases. Transcreener assays are the only method for direct detection of nucleotide enzyme products, which provides significant advantages over other HTS enzyme assay methods in terms of sensitivity, signal stability and resistance to interference. They are designed for an automated HTS environment with single addition, mix-and-read format and overnight reagent and signal stability and are available in three different fluorescent readouts; FI, FP and TR-FRET.

Cambio will also distribute BellBrook’s new Transzyme™ product line of turn-key methyltransferase assay kits that combine pre-calibrated purified methyltransferase enzymes and substrates from Reaction Biology with BellBrook’s Transcreener EPIGEN Methyltransferase detection reagents. The Transzyme kits allow investigators to start screening or profiling methyltransferases without the costly reagent testing and assay development normally associated with these complex enzyme systems.

About BellBrook Labs. BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. Visit BellBrook’s website for more information: http://www.bellbrooklabs.com.

About Cambio. Established in 1985, Cambio is a privately-held UK company with an excellent reputation for the supply of high quality molecular biology reagents and consumables. To meet the needs of a growing and diversifying market, advanced Molecular Biology products are continually added to the company’s extensive portfolio. This wide choice of research tools sourced from a global network of leading manufacturers is complemented by Cambio’s commitment to world-class technical support and customer service. As a result, the company has built successful long-term customer relationships with scientific research laboratories within universities, large pharma and biotech companies, government agencies, agricultural organisations and environmental facilities. Based near Cambridge, UK, Cambio is ISO9001:2008 registered. http://www.cambio.co.uk/

Read the full story at http://www.prweb.com/releases/2013/4/prweb10643831.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cytos Biotechnology Strengthens Management Team
2. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
3. Molecular Detection Inc. Further Strengthens Patent Portfolio Broadly Covering Detection of Antibiotic-Resistant Bacteria
4. AMRI Strengthens Business Development and Marketing Groups
5. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
6. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
7. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Finesse Solutions and ATMI Sign Distribution Agreement for Turnkey Bioreactor Systems
10. Chemical Publishing Company Partners with Author Cloudware for a Digital eBook Distribution for Water Treatment, Waste Water Treatment, and Cooling Water Treatment Titles
11. Professional Pricing Society Survey Reveals 12 Percent Gain in Manufacturing and Distribution Salaries, Indicating Growing Value of Pricing Expertise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):